CHM 0.00% 1.4¢ chimeric therapeutics limited

Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-11

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,200 Posts.
    lightbulb Created with Sketch. 3885
    Just noticed that the CHM 0201 Vactosertib trial is currently suspended (temporarily) due to insufficient staff (Christmas break?):

    https://hotcopper.com.au/data/attachments/5860/5860986-3879d67610f54b2ef452d1ded52a2f78.jpg
    https://clinicaltrials.gov/study/NCT05400122?tab=table

    Primary Completion Date however remains unchanged (Estimated): 1 June 2024.

    Given the time Primary Outcome (1.) being 28 days after infusion, that would indicate dosing of the last patient to occur beginning of May (estimated).

    Also worth noting that the trial seeks to enrol "up to 12 patients":
    https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.TPS273

    https://hotcopper.com.au/data/attachments/5861/5861080-55de45ac2829553157880296643a0d48.jpg

    https://chimerictherapeutics.com/our-pipeline/#our-pipeline

    This trial is not the same as the ADVENT-AML Phase 1B trial:
    https://clinicaltrials.gov/study/NCT05834244

    https://hotcopper.com.au/data/attachments/5861/5861075-9363ba3c3709228378a06f2263f0dc17.jpg
    https://chimerictherapeutics.com/our-pipeline/#our-pipeline


    Both trials are utilising the non-engineered allogeneic CORE-NK platform (CHM 0201), which is different to the autologous therapy CHM 1101 (CLTX), which recently dosed the last patient in a Phase 1A dose escalation study:
    https://clinicaltrials.gov/study/NCT04214392

    https://hotcopper.com.au/data/attachments/5861/5861150-afa953f35365d9b88a7e3527883b06ed.jpg
    https://www.businessnews.com.au/article/Chimeric-moves-US-brain-cancer-trial-to-next-stage

    Positive Preliminary Data was announced in October last year:

    https://hotcopper.com.au/data/attachments/5861/5861172-c788a257f931d1b03f62d35d76b7702a.jpg
    https://chimerictherapeutics.com/wp-content/uploads/2023/10/ASX-Announcement-23Oct2023-2627696.pdf

    CLTX is currently tested in a Phase 1B trial:
    https://clinicaltrials.gov/study/NCT05627323

    https://hotcopper.com.au/data/attachments/5861/5861077-ad299c158835823ba0c72c29d96ee919.jpg
    https://chimerictherapeutics.com/our-pipeline/#clinical-trials

    CHM 2101, an autologous CDH17 CAR T-cell therapy is due to start recruitment within the next 6 months in a Phase 1 dose escalation study, with Phase 2 dosing based on results from Phase 1:
    https://classic.clinicaltrials.gov/ct2/show/NCT06055439


    So much to see here...
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.